Transcriptional dysregulation in Huntington's disease: A failure of adaptive transcriptional homeostasis

Drug Discovery Today

Volumn 19, Issue 7, 2014, Pages 956-962

  Kumar, Amit ^a,b   Vaish, Manisha ^a   Ratan, Rajiv R ^a,b,c  

^a BURKE MEDICAL RESEARCH INSTITUTE   (United States)

^b Brain and Mind Research Institute Weill Medical College Cornell University ^*  (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; HUNTINGTIN; TRANSCRIPTION FACTOR; HTT PROTEIN, HUMAN; NERVE PROTEIN;

BEHAVIOR CHANGE; CELL NUCLEUS INCLUSION BODY; DEACYLATION; GENE REPRESSION; HISTONE ACETYLATION; HISTONE MODIFICATION; HOMEOSTASIS; HUNTINGTON CHOREA; NONHUMAN; OXIDATIVE STRESS; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SYNAPSE; ANIMAL; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; MUTATION; PHYSIOLOGY;

ANIMALS; HOMEOSTASIS; HUMANS; HUNTINGTON DISEASE; MUTATION; NERVE TISSUE PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84903755463     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.03.016     Document Type: Review

References (68)

1. R.J. Ferrante et al. Selective sparing of a class of striatal neuron in Huntington's disease Science 230 1985 561 564
2. H.P. Gerber et al. Transcriptional activation modulated by homopolymeric glutamine and proline stretches Science 263 1994 808 811
3. M. DiFiglia et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neuritis in brain Science 277 1997 1990 1993
4. S.C. Warby et al. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus Hum. Mol. Genet. 17 2008 2390 2404
5. L.S. Havel et al. Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation Hum. Mol. Genet. 20 2011 1424 1437
6. Z. Zheng et al. An N-terminal nuclear export signal regulates trafficking and aggregation of huntingtin (Htt) protein exon 1 J. Biol. Chem. 288 2013 6063 6071
7. F. Saudou et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions Cell 95 1998 55 66
8. G. Schilling et al. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice Hum. Mol. Genet. 13 2004 1599 1610 (Pubitemid 39136716)
9. C.L. Benn et al. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease Hum. Mol. Genet. 14 2005 3065 3078 (Pubitemid 41535471)
10. R. Luthi-Carter et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain Hum. Mol. Genet. 11 2002 1911 1926
11. R.K. Graham et al. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo J. Neurosci. 30 2010 15019 15029
12. R. Luthi-Carter et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease Hum. Mol. Genet. 9 2000 1259 1271 (Pubitemid 30312475)
13. A. Hodges et al. Regional and cellular gene expression changes in human Huntington's disease brain Hum. Mol. Genet. 15 2006 965 977 (Pubitemid 43338237)
14. R. Luthi-Carter, and J.-H.J. Cha Mechanisms of transcriptional dysregulation in Huntington's disease Clin. Neurosci. Res. 3 2003 165 177 (Pubitemid 37168738)
15. A. Kazantsev et al. Insoluble detergent-resistant aggregates form between pathological and non-pathological lengths of polyglutamine in mammalian cells Proc. Natl. Acad. Sci. U. S. A. 96 1999 11404 11409 (Pubitemid 29487393)
16. F.C. Nucifora Jr. et al. Interference by huntingtin and atrophin-1 with CBP mediated transcription leading to cellular toxicity Science 291 2001 2423 2428
17. G. Sadri-Vakili et al. Huntingtin inclusions do not downregulate specific genes in the R6/2 Huntington's disease mouse Eur. J. Neurosci. 23 2006 3171 3175
18. Z.X. Yu et al. Huntingtin inclusions do not deplete polyglutamine- containing transcription factors in HD mice Hum. Mol. Genet. 11 2002 905 914
19. II130 transcriptional activity disrupted in early Huntington's disease Science 296 2002 2238 2243 (Pubitemid 34680312)
20. A.S. Chen-Plotkin et al. Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease Neurobiol. Dis. 22 2006 233 241
21. Z. Qiu et al. Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective J. Biol. Chem. 281 2006 16672 16680
22. R.J. Ferrante et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease J. Neurosci. 24 2004 10335 10342 (Pubitemid 39552617)
23. S.F. Sleiman et al. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration J. Neurosci. 31 2011 6858 6870
24. K.L. Sugars et al. Decreased cAMP response element mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis J. Biol. Chem. 279 2004 4988 4999 (Pubitemid 38199095)
25. L. Cui et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration Cell 127 2006 59 69 (Pubitemid 44466642)
26. S.J. McConoughey et al. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease EMBO Mol. Med. 2 2010 349 370
27. J. Lee et al. Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival J. Biol. Chem. 280 2005 40398 40401 (Pubitemid 41780525)
28. J.S. Steffan et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila Nature 413 2001 739 743 (Pubitemid 33009952)
29. A. Giralt et al. Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity Hum. Mol. Genet. 21 2012 1203 1216
30. G. Sadri-Vakili, and J.H. Cha Mechanisms of disease: histone modifications in Huntington's disease Nat. Clin. Pract. Neurol. 2 2006 330 338 (Pubitemid 43811543)
31. A. Bithell et al. Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease Biochem. Soc. Trans. 37 2009 1270 1275
32. C. Zuccato et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease Science 293 2001 493 498 (Pubitemid 32679077)
33. C. Zuccato et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes Nat. Genet. 35 2003 76 83 (Pubitemid 37048599)
34. R. Johnson et al. A microRNA-based gene dysregulation pathway in Huntington's disease Neurobiol. Dis. 29 2008 438 445
35. A. Packer et al. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease J. Neurosci. 28 2008 14341 14346
36. R. Wang et al. Sp1 regulates human huntingtin gene expression J. Mol. Neurosci. 47 2012 311 321
37. R. Luthi-Carter et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context independent effects Hum. Mol. Genet. 11 2002 1927 1937 (Pubitemid 34919269)
38. S.T. Suhr et al. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression J. Cell Biol. 153 2001 283 294 (Pubitemid 34280215)
39. W. Zhai et al. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets Cell 123 2005 1241 1253 (Pubitemid 41821782)
40. G. Gardian et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease J. Biol. Chem. 280 2005 556 563 (Pubitemid 40165021)
41. K.N. McFarland et al. Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease PLoS ONE 7 2012 e41423
42. J.S. Steffan et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription Proc. Natl. Acad. Sci. U. S. A. 97 2000 6763 6768 (Pubitemid 30412788)
43. H. Ryu et al. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease Proc. Natl. Acad. Sci. U. S. A. 103 2006 19176 19181 (Pubitemid 350002846)
44. M.O. Kim et al. Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation J. Neurosci. 28 2008 3947 3957
45. M. Vashishtha et al. Targeting H3K4 trimethylation in Huntington disease Proc. Natl. Acad. Sci. U. S. A. 110 2013 E3027 E3036
46. T.M. Jeitner et al. Increased levels of gamma-glutamylamines in Huntington disease CSF J. Neurochem. 106 2008 37 44 (Pubitemid 351850209)
47. C.L. Benn et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner J. Neurosci. 28 2008 10720 10733
48. M. Hogel et al. Promoters are differentially sensitive to N-terminal mutant huntingtin-mediated transcriptional repression PLoS ONE 7 2012 e41152
49. T. Milakovic, and G.V. Johnson Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin J. Biol. Chem. 280 2005 30773 30782 (Pubitemid 41291807)
50. T. Milakovic et al. Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences J. Biol. Chem. 281 2006 34785 34795 (Pubitemid 46036517)
51. X.J. Li et al. Impaired mitochondrial trafficking in Huntington's disease Biochim. Biophys. Acta 1802 2010 62 65
52. F. Squitieri et al. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for huntington disease mutation Mech. Ageing Dev. 127 2006 217 220 (Pubitemid 43165622)
53. R.R. Ratan et al. Harnessing hypoxic adaptation to prevent, treat, and repair stroke J. Mol. Med. 85 2007 1331 1338 (Pubitemid 50005503)
54. T. Tsunemi et al. PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function Sci. Transl. Med. 4 2012 142ra97
55. Z. DeMarch et al. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity Neurobiol. Dis. 25 2007 266 273
56. C. Giampa et al. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease Neurobiol. Dis. 34 2009 450 456
57. P. Conforti et al. Binding of the repressor complex REST-mSIN3b by small molecules restores neuronal gene transcription in Huntington's disease models J. Neurochem 2013 10.1111/jnc.12348
58. P. Conforti et al. In vivo delivery of DN:REST improves transcriptional changes of REST-regulated genes in HD mice Gene Ther. 20 2013 678 685
59. C. Soldati et al. Rescue of gene expression by modified REST decoy oligonucleotides in a cellular model of Huntington's disease J. Neurochem. 116 2011 415 425
60. J. Jin et al. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease J. Neurochem. 125 2013 410 419
61. H. Ryu et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway Proc. Natl. Acad. Sci. U. S. A. 100 2003 4281 4286 (Pubitemid 36418194)
62. R.J. Ferrante et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice J. Neurosci. 23 2003 9418 9427 (Pubitemid 37323042)
63. E.A. Bates et al. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity J. Neurosci. 26 2006 2830 2838 (Pubitemid 43357867)
64. J. Pallos et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease Hum. Mol. Genet. 17 2008 3767 3775
65. E.A. Thomas et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice Proc. Natl. Acad. Sci. U. S. A. 105 2008 15564 15569
66. V. Chopra et al. The Sirtuin 2 inhibitor AK-7 is neuroprotective in huntington disease mouse models Cell Rep. 2 2013 1492 1497
67. T. Hathorn et al. Nicotinamide improves motor deficits and upregulates PGC-1alpha and BDNF gene expression in a mouse model of Huntington's disease Neurobiol. Dis. 41 2011 43 50
68. K.F.S. Bell, and G.E. Hardingham The influence of synaptic activity on neuronal health Curr. Opin. Neurobiol. 21 2011 299 305